There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for KYTX is 19.21M, and at present, short sellers hold a 16.81% of that float. The average trading volume of KYTX on July 04, 2024 was 600.49K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KYTX) stock’s latest price update
Kyverna Therapeutics Inc. (NASDAQ: KYTX)’s stock price has plunge by -2.11relation to previous closing price of 8.05. Nevertheless, the company has seen a 8.39% surge in its stock price over the last five trading sessions. accesswire.com reported 2024-07-03 that LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. (“Rivian” or “the Company”) (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
KYTX’s Market Performance
Kyverna Therapeutics Inc. (KYTX) has seen a 8.39% rise in stock performance for the week, with a -39.71% decline in the past month and a -64.05% plunge in the past quarter. The volatility ratio for the week is 10.18%, and the volatility levels for the past 30 days are at 15.00% for KYTX. The simple moving average for the last 20 days is -22.40% for KYTX stock, with a simple moving average of -59.69% for the last 200 days.
Analysts’ Opinion of KYTX
Wells Fargo, on the other hand, stated in their research note that they expect to see KYTX reach a price target of $44. The rating they have provided for KYTX stocks is “Overweight” according to the report published on March 04th, 2024.
Morgan Stanley gave a rating of “Overweight” to KYTX, setting the target price at $40 in the report published on March 04th of the current year.
KYTX Trading at -38.85% from the 50-Day Moving Average
After a stumble in the market that brought KYTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.52% of loss for the given period.
Volatility was left at 15.00%, however, over the last 30 days, the volatility rate increased by 10.18%, as shares sank -40.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.62% lower at present.
During the last 5 trading sessions, KYTX rose by +5.64%, in comparison to the 20-day moving average, which settled at $9.89. In addition, Kyverna Therapeutics Inc. saw -73.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KYTX starting from GILEAD SCIENCES, INC., who purchase 910,000 shares at the price of $22.00 back on Feb 12 ’24. After this action, GILEAD SCIENCES, INC. now owns 4,126,119 shares of Kyverna Therapeutics Inc., valued at $20,020,000 using the latest closing price.
Northpond Ventures III GP, LLC, the Former 10% Owner of Kyverna Therapeutics Inc., purchase 450,000 shares at $22.00 during a trade that took place back on Feb 12 ’24, which means that Northpond Ventures III GP, LLC is holding 450,000 shares at $9,900,000 based on the most recent closing price.
Stock Fundamentals for KYTX
The liquidity ratio also appears to be rather interesting for investors as it stands at 17.17.
Conclusion
In summary, Kyverna Therapeutics Inc. (KYTX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
